German biotech company bitop AG announced that it has begun enrolling patients in a clinical trial of its Ectoin inhalation solution for the treatment of airway inflammation. In addition to the inhalation solution, bitop is also developing an Ectoin nasal spray and and a DPI. According to bitop, Ectoin is a naturally-occurring "cell protection molecule." Read the company’s press release.
Bitop initiates trial of Ectoin inhalation solution
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA